The Efficacy of Generic Imatinib in Treatment of Chronic Myeloid Leukemia
Abstract
Background: Chronic myeloid leukemia (CML) accounts for 15% of all adult leukemia, and is characterized by a translocation between chromosomes 9 and 22 (Philadelphia chromosome) and results in the mutant BCR-ABL gene. Most cases of chronic myeloid leukemia are diagnosed during the chronic phase, and in this case, tyrosine kinase inhibitors has increased survival and improved quality of life. The use of generic drug reduces costs and increases the chance of treating as many patients as possible. This study aim to evaluate the effectiveness of generic Imatinib in the treatment of chronic myeloid leukemia.
Methods: This study is a retrospective study in a single center (Albaironi University Hospital in Damascus), we evaluate the hematological, chromosomal and molecular response in patients with chronic myeloid leukemia during the chronic phase and treated with generic Imatinib during 2009.
Results: 28 patients were evaluated. A complete hematological response occurred after 3 months in all patients (100%). After 6 months, a major molecular response (MMR) occurred in 14 patients (50%) and a Complete cytogenetic response (CCyR) in 3 patients (10.7%). The response was studied after 12 months in 26 patients and a MMR occurred in 5 patients (19.2%) and a CCyR in 10 patients (38.5%).
Conclusion: The use of generic Imatinib resulted in a hematological, chromosomal and molecular response and is effective in the treatment of chronic myeloid leukemia.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.